NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDAbatacept Orencia® Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
SCGMethotrexate
(For rheumatology - SCG)
 
Musculoskeletal and joint diseases, Drugs affecting the immune response, 10.01.03
REDSarilumab 150mg, 200mg
(Pre-filled pen or syringe)
 
Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
SCGSulfasalazine  Musculoskeletal and joint diseases, Sulfasalazine, 10.01.03
REDTetracosactide 1mg Synacthen Depot ®
(Injection)
 
Endocrine system, Hypothalamic and anterior pituitary hormones and anti-oestrogens, 06.05.01
REDUstekinumab 45mg, 90mg Pyzchiva® Wezenla®
(Pre-filled syringe)
 
Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
Non Formulary items found
Status Description Section
 Capsaicin 0.025% Zacin®
(Cream)
 
Musculoskeletal and joint diseases, Capsaicin, 10.03.02
DNPHyaluronic acid  Musculoskeletal and joint diseases, Osteoarthritis and soft-tissue disorders, 10.01
DNPHylan G-F 20 Synvisc® Musculoskeletal and joint diseases, Osteoarthritis and soft-tissue disorders, 10.01
DNPSodium hyaluronate and triamcinolone hexacetonide Cingal Musculoskeletal and joint diseases, Osteoarthritis and soft-tissue disorders, 10.01
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Abatacept Abatacept Musculoskeletal System, Arthritis, Immunosuppressants T-Cell Activation Inhibitors
Aceclofenac Aceclofenac Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Adalimumab Adalimumab Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Anakinra Anakinra Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Apremilast Apremilast Musculoskeletal System, Arthritis
Azathioprine Azathioprine Musculoskeletal System, Arthritis, Immunosuppressants Antimetabolites
Baricitinib Baricitinib Musculoskeletal System, Arthritis, Immunosuppressants JAK Inhibitors
Bimekizumab Bimekizumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Capsaicin Capsaicin Musculoskeletal System, Arthritis, Analgesics Plant Alkaloids
Celecoxib Celecoxib Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Certolizumab  Certolizumab Pegol Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Chloroquine  Chloroquine Musculoskeletal System, Arthritis, Antiprotozoals Antimalarials
Ciclosporin Ciclosporin Musculoskeletal System, Arthritis, Immunosuppressants Calcineurin Inhibitors And Related Drugs
Cyclophosphamide Cyclophosphamide Musculoskeletal System, Arthritis, Antineoplastic Drugs Alkylating Agents
Diclofenac Diclofenac Potassium Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Diclofenac Diclofenac Sodium Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Etanercept Etanercept Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Etodolac Etodolac Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Etoricoxib  Etoricoxib Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Filgotinib Filgotinib Musculoskeletal System, Arthritis, Immunosuppressants JAK Inhibitors
Flurbiprofen Flurbiprofen Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Glucosamine Glucosamine Musculoskeletal System, Arthritis
Golimumab Golimumab Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Guselkumab Guselkumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Hydroxychloroquine Hydroxychloroquine Sulfate Musculoskeletal System, Arthritis
Ibuprofen Ibuprofen Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Indometacin Indometacin Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Infliximab Infliximab Musculoskeletal System, Arthritis, Immunosuppressants Tumor Necrosis Factor Alpha (TNF-A) Inhibitors
Ixekizumab Ixekizumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Ketoprofen Ketoprofen Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Leflunomide Leflunomide Musculoskeletal System, Arthritis
Mefenamic  Mefenamic Acid Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Meloxicam Meloxicam Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Methotrexate Methotrexate Musculoskeletal System, Arthritis, Antineoplastic Drugs Antimetabolites
Nabumetone Nabumetone Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Naproxen Naproxen Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Penicillamine Penicillamine Musculoskeletal System, Arthritis
Penicillamine Penicillamine Musculoskeletal System, Arthritis, Antidotes And Chelators Copper Chelators
Piroxicam Piroxicam Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Risankizumab Risankizumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Rituximab  Rituximab Musculoskeletal System, Arthritis, Antineoplastic Drugs Monoclonal Antibodies
Sarilumab  Sarilumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Secukinumab  Secukinumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Sulfasalazine Sulfasalazine Musculoskeletal System, Arthritis
Sulindac Sulindac Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Tenoxicam Tenoxicam Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Tiaprofenic  Tiaprofenic Acid Musculoskeletal System, Arthritis, Analgesics Non-Steroidal Anti-Inflammatory Drugs
Tocilizumab Tocilizumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Tofacitinib Tofacitinib Musculoskeletal System, Arthritis, Immunosuppressants JAK Inhibitors
Upadacitinib Upadacitinib Musculoskeletal System, Arthritis, Immunosuppressants JAK Inhibitors
Ustekinumab  Ustekinumab Musculoskeletal System, Arthritis, Immunosuppressants Interleukin Inhibitors
Links found
BLMK APC Biologics Treatment pathway for Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (nrAxial SpA)
BLMK APC Treatment Pathway for Active Psoriatic Arthritis (non-Axial PsA) after inadequate response to DMARDs
BLMK APC Treatment pathway for Moderate Rheumatoid Arthritis
BLMK APC Treatment Pathway for Severe Rheumatoid Arthritis
JPC Biologics Treatment Pathway for ankylosing spondylitis and Non-radiographic Axial Spondyloarthritis (March 2018)
MHRA DSU 2016: Etoricoxib (Arcoxia): revised dose recommendation for rheumatoid arthritis and ankylosing spondylitis
NICE TA 433: Apremilast for treating active psoriatic arthritis
NICE TA 715 Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE TA 719 Secukinumab for treating non-radiographic axial spondyloarthritis, Technology appraisal guidance
NICE TA1104: Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (TERMINATED APPRAISAL)
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (NICE TA199)
NICE TA220: Psoriatic arthritis - golimumab
NICE TA225: Rheumatoid arthritis - golimumab
NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198)
NICE TA340 - treating active psoriatic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE TA375:Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
NICE TA711: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA735 Tofacitinib for treating juvenile idiopathic arthritis
NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA803 Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA803: Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
NICE TA916: Bimekizumab for treating active psoriatic arthritis
NICE TA918: Bimekizumab for treating axial spondyloarthritis
NICE TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (TERMINATED APPRAISAL)
TA676 Filgotinib for treating moderate to severe rheumatoid arthritis